Johnson & Johnson Announces Updated Results From The Investigational Phase 1b Trimm-2 Study Evaluating The Combination Of TALVEY And DARZALEX FASPRO Based Combination Shows Deep And Durable Responses In Patients With Relapsed Or Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson announced promising results from the Phase 1b TRIMM-2 study, showing a 100% overall response rate in a weekly dosing arm for a combination therapy involving TALVEY and DARZALEX FASPRO in patients with relapsed or refractory multiple myeloma.
September 27, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's Phase 1b TRIMM-2 study shows a 100% overall response rate in a weekly dosing arm for a combination therapy involving TALVEY and DARZALEX FASPRO in multiple myeloma patients, indicating strong potential for this treatment.
The study results indicate a high efficacy of the combination therapy, which could lead to increased adoption and sales if approved, positively impacting JNJ's stock price. The 100% response rate in the weekly dosing arm is particularly noteworthy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100